Microbot Medical Secures New Patents, Expands Global IP Portfolio

Microbot Medical Inc. (Nasdaq: MBOT) has received multiple new patent approvals across the U.S., Japan, China, and Canada, strengthening its global intellectual property position as it expands commercial adoption of its LIBERTY Endovascular Robotic System. The company now holds 44 issued patents and 49 pending patent applications across North America, Europe, Israel, and Asia. These approvals are part of a broader strategy to protect innovations and support market expansion in both the U.S. and international markets, where the company is currently pursuing a CE Mark for the EU.

Dr. Sarit Garten, Director of Intellectual Property at Microbot Medical, stated that the company’s commercial growth since the launch of LIBERTY is aligned with efforts to enhance its intellectual property portfolio while building the global infrastructure necessary for broader market access. He noted that ongoing collaboration between research and development and business development teams is resulting in a diverse portfolio that the company expects to expand significantly in the coming months. These developments are intended to align with the company’s strategy for market entry into the EU and other jurisdictions.

The LIBERTY system is an FDA-cleared, single-use, remotely operated robotic system designed for peripheral endovascular procedures. It is engineered for precise vascular navigation with the aim of reducing radiation exposure and physical strain for operators. Microbot Medical describes itself as a commercial-stage medical device company focused on transforming endovascular care through advanced robotic technology. The company’s approach combines its growing patent estate with a commitment to innovation to drive the future of endovascular procedures.

The company provided forward-looking statements regarding future financial results, product adoption, and growth in research and commercialization. These statements involve risks and uncertainties, including market conditions, the commercialization of the LIBERTY system, regulatory approval pathways, and geopolitical factors such as hostilities in the Middle East. Additional risk information is available in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission.